Blog

Bernard A. Fox: A new generation of immunotherapy clinical trials

Bernard Fox/LinkedIn

Jul 1, 2024, 17:27

Bernard A. Fox: A new generation of immunotherapy clinical trials

Bernard A. Fox, Co-Founder and CEO of UbiVac shared on LinkedIn:

“Great to be in Marseille with colleagues from Switzerland, Germany, Canada, and Singapore for the review of the Immunopole Pioneer Project efforts to cure patients of lung cancer. This 6 yr program has accumulated a wealth of blood and tissue biomarkers that are an incredible resource and will aid in the development of a new generation of immunotherapy clinical trials! BRAVO Fabrice Barlesi & the entire team who contributed to this effort. The meetings were held in what was Marseille’s 1st medical school Aix-Marseille Université (AMU) and overlook the Marina that will be the Paris 2024 International Olympic Committee – IOC sailing venue.”

Source: Bernard A. Fox/LinkedIn
.

Aix-Marseille Université AMU Bernard A. Fox biomarkers cancer cancer treatment clinical trials Fabrice Barlesi Immunopole Pioneer Project immunotherapy International collaboration Lung cancer Marseille OncoDaily Oncology oncology research Paris 2024 Olympics UbiVac

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage